ADPT vs VNDA: fair value comparison
Adaptive Biotechnologies Corporation and Vanda Pharmaceuticals Inc. · Updated 2026-10-19
ADPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. VNDA is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, VNDA currently ranks higher by quality score.
| ADPT | VNDA | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $24.02 | $4.03 |
| 12-month range | $12.41–$29.84 | $4.03–$9.56 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #141 of 301 Healthcare | #139 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: ADPT fair value analysis · VNDA fair value analysis